biolitec makes swift progress in BPH market penetration in the USA

Nationwide rental network established. 40% market share expected by end of 2008

Jena, (PresseBox) - Partnering with 10 rental companies and LLCs recently biolitec's strategy to broaden its market coverage significantly via rental companies in the USA is succeeding faster than expected. biolitec AG, listed in the Prime Standard of the Frankfurt stock exchange (ISIN DE0005213409), can now point to a nationwide coverage network enabling the training and familiarisation of physicians and hospitals for its innovative BPH treatment procedure.

As rental companies including LLCs make up the bulk of the market biolitec forecasts to take its present 20percent share to 40 percent of procedures performed within the next 12 months. Approx 85 000 BPH procedures annually are currently performed with lasers in the USA. Rental companies bill 1000 to 1500 dollar on a per case basis.

In addition the US nationwide sales force hiring was completed for the office market segment.

In Germany, the world’s second largest laser BPH market recently new, significantly improved reimbursement possibilities have been suggested to take effect from January 1st, 2008 that should pave the way for a significantly increased adoption of biolitec's technology.
The company expects to significantly exceed its previous targets here as well.
In 2008 in total 60 lasers should be placed in Germany alone and 6000 procedures are planned to be performed with biolitec's LIFE procedure to treat BPH.

Benign prostate hyperplasia (BPH) affects approx. 50 % of men over 50 and 80% of men over 80. Classical electro resection leads to significant blood loss, long reconvalescence time and carries significant side effect risks. biolitec laser vaporization procedure (LIFE - Laser Induced Flow Enhancement) avoids this disadvantages
and is suitable for a hospital as well as an office setting.

biolitec biomedical technology GmbH

biolitec ist weltweit der einzige Anbieter für die photodynamische Therapie, der über alle relevanten Kernkompetenzen - Photosensitizer, Laser, Lichtwellenleiter und ein in Europa zugelassenes Arzneimittel mit dem Wirkstoff Temoporfin® - verfügt. Neben minimal-invasiven Laserbehandlungen und dem Geschäftsfeld Onkologie hat sich die biolitec AG einzigartige Kompetenzen im Bereich Ästhetik erworben. biolitec ist im Prime Standard unter der ISIN DE0005213409 notiert. Weitere Informationen zum LIFETM Laser sind auf

Press releases you might also be interested in

Subscribe for news

The subscribtion service of the PresseBox informs you about press information of a certain topic by your choice at a choosen time. Please enter your email address to receive the email with the press releases.

An error occurred!

Thank you! You will receive a confirmation email within a few minutes.

I want to subscribe to the gratis press mail and have read and accepted the conditions.